BeyondSpring Presents Updated Efficacy Results From a Phase 2 IIT Study of Triple IO Combo of Pembrolizumab Plus Plinabulin/Docetaxel in Metastatic NSCLC After Progressing on Prior Immune Checkpoint Inhibitors at the 39th SITC Annual Meeting

GlobeNewswire11/11 21:00

12 Health Care Stocks Moving In Tuesday's Intraday Session

Benzinga10/02 00:31

BeyondSpring Presents Final Data Analysis of DUBLIN-3 Phase 3 Study in 2L/3L EGFR Wild-type NSCLC at ESMO Congress 2024

GlobeNewswire09/16 19:00

BeyondSpring Presents Efficacy/Safety Results From a Phase 2 Study of Pembrolizumab Plus Plinabulin/Docetaxel in Metastatic NSCLC After Progressing on First-Line Immune Checkpoint Inhibitors at ESMO Congress 2024

BeyondSpring09/16 12:00

BeyondSpring Presents Final Phase 3 Results For Plinabulin In 2L/3L NSCLC At ISLAC 2024, With Concurrent Publication In The Lancet Respiratory Medicine

Benzinga09/10 19:44

BeyondSpring Announces Oral Presentation at the 2024 World Conference on Lung Cancer and Two Poster Presentations During ESMO Congress 2024 Showcasing Its Lead Anti-Cancer Asset, Plinabulin

Yahoo Finance09/03 19:00